Atezolizumab Trial for NSCLC with Brain Metastases Terminated Early

Trial results for the Phase 2 study investigating atezolizumab in combination with tiragolumab for non-squamous non-small cell lung cancer (NSCLC) with untreated brain metastases were posted on ClinicalTrials.gov on 2026-01-22. The study, which was terminated early, enrolled only 3 participants. Among these, 0 participants initiated salvage radiation therapy to the central nervous system.

Background

The study, titled 'Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases,' aimed to evaluate the safety and clinical activity of tiragolumab in combination with atezolizumab, with or without chemotherapy, as a first-line treatment for metastatic non-squamous NSCLC patients with asymptomatic untreated brain metastases.

Trial design

The study (NCT05746481) was a Phase 2 clinical trial that was ultimately terminated. It enrolled 3 participants diagnosed with Non-small Cell Lung Cancer. The trial investigated tiragolumab and atezolizumab, with or without pemetrexed and carboplatin, in patients with untreated brain metastases.

Key results

The trial reported key measurements from the Single Treatment Arm. For the outcome 'Rate of Initiation of Salvage Radiation Therapy to Central Nervous System (CNS)', 0 participants initiated this therapy. Adverse Events Related to Treatment were reported, with participant counts ranging from 1 to 3 across different event categories.

What this means

The early termination of this Phase 2 trial with only 3 participants means that no conclusive data on the efficacy or safety of tiragolumab and atezolizumab in this specific population can be drawn from this study. While 0 participants initiated salvage radiation therapy to the CNS, the extremely limited enrollment prevents any meaningful interpretation of this finding. The trial's termination indicates that further investigation in this exact design was not pursued.

Source

The information for these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT05746481, titled 'Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases,' were posted on 2026-01-22 on clinicaltrials.gov.